|
name  click to compare prices |
» Shop local, ethical and at the best price on Ethishop  |
|
|
« Ethical » rating of Boehringer
, group
and subsidiaries
|
Fraud 1
Offshore 1
Influence 4
| [click on the rating for the method or on the number for the data]
|
|
Shareholders
Business & market
Locations & production
year | financial misdemeanor | | | assets | | source |
2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | |   | | Canadian Press |
1998 |
| | | 7,1 |   | billion US$ | Forbes |
|
year | financial misdemeanor | sales | income | assets | buyback | source |
|
|
|